Doxycycline hyclate 100 MG VLS
Ended Awarded
- Contract number
- SPE2D325F214Z
- Awardee
-
Hikma Pharmaceuticals USA Inc. UEI NQJ5E87TKNB1 Part of Hikma Specialty USA Inc.
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $83,546
Award facts
- Contract value 100% obligated
- $83,545.99 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Berkeley Heights, NJ 07922, USA
Award details come from SAM.gov/FPDS.
About this award
The U.S. Department of Defense Medical Supply Chain awarded a $83,546 firm fixed-price delivery order to Hikma Pharmaceuticals USA Inc. (formerly West-Ward Pharmaceuticals) for Doxycycline Hyclate 100 mg on July 14, 2025, with a completion date of July 15, 2025. The order will be fulfilled at the contractor's facility in Berkeley Heights, New Jersey. This delivery order was issued without a small business set-aside designation and represents a continuation of Hikma's role as a critical supplier of generic pharmaceutical products to federal healthcare systems. Hikma Pharmaceuticals USA Inc., a foreign-owned pharmaceutical manufacturer, is registered in the System for Award Management and specializes in producing generic injectable and non-injectable medications for military treatment facilities and government healthcare networks.
This contract award is likely executed under one of Hikma's existing Indefinite Delivery Vehicles, including the company's $216 million multiple-award Federal Supply Schedule contract with the Department of Veterans Affairs for pharmaceuticals and hematology-related products, or through the Defense Logistics Agency's medical supply ordering mechanisms. Doxycycline hyclate is an essential broad-spectrum antibiotic critical to military medical readiness and deployed forces' healthcare operations. The award reflects Hikma's established position as a reliable supplier of essential medications to the Department of Defense and other federal healthcare agencies, with a track record of delivering diverse pharmaceutical products including injectable solutions, controlled substances, and routine medications to support military personnel, veterans, and their dependents.
Quick answers
Who was awarded contract SPE2D325F214Z?
SPE2D325F214Z was awarded to Hikma Pharmaceuticals USA Inc. by Medical Supply Chain (Troop Support) on July 14, 2025.
How much is contract SPE2D325F214Z worth?
The government has obligated $83,546 on SPE2D325F214Z.
Is contract SPE2D325F214Z an order under another contract?
Yes. SPE2D325F214Z is a delivery order under SPE2D020D0006, an indefinite delivery contract.
Was contract SPE2D325F214Z competed?
The extent of competition for SPE2D325F214Z was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award